Abnormal late postprandial glucagon response in type 1 diabetes is a function of differences in stimulated C-peptide concentrations

被引:0
作者
Zhang, Lingyu [1 ,2 ]
Qin, Yao [1 ]
Huang, Yiting [1 ]
Hu, Qizhen [1 ]
Wu, Qian [1 ]
Wang, Xing [1 ]
Zhang, Mei [1 ]
机构
[1] Nanjing Med Univ, Affiliated Hosp 1, Dept Endocrinol, Nanjing, Jiangsu, Peoples R China
[2] Nanjing Med Univ, Changzhou Peoples Hosp 2, Dept Endocrinol, Changzhou, Jiangsu, Peoples R China
来源
FRONTIERS IN ENDOCRINOLOGY | 2024年 / 15卷
基金
中国国家自然科学基金;
关键词
type; 1; diabetes; alpha cell regulation; glucagon; stimulated C-peptide; late glucagon response; RECEPTOR ANTIBODY; INSULIN; SECRETION; HYPERGLUCAGONEMIA; PREVALENCE; ONSET; YOUTH;
D O I
10.3389/fendo.2024.1419329
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The functional changes in alpha cells in patients with type 1 diabetes (T1D) with different residual beta cell functions remain poorly elucidated. The study aimed to investigate the relationship between glucagon secretion and C-peptide levels and to explore the relationship between glucagon response and glucose increment in respond to a secretagogue in a steamed bread meal tolerance test (BMTT) in T1D. Methods The study enrolled 43 adult patients with T1D and 24 healthy control subjects. Patients with T1D who underwent BMTT were divided into two groups based on peak C-peptide levels: C peptide low (CPL; C-peptide < 200 pmol/L; n=14) and high (CPH; C peptide >= 200 pmol/L; n=29). Plasma glucose, C-peptide, glucagon levels at 0, 30, 60, 120, and 180 min were measured. The glucagon response to the BMTT was defined by areas under the curve (AUC) as early (AUC0-30), late (AUC30-180), or total (AUC0-180) glucagon. Results Compared to healthy individuals, fasting plasma glucagon was lower and postprandial plasma glucagon level was increased in patients with T1D. Glucagon levels after BMTT between the CPL and CPH group showed significant group by time interaction. Peak glucagon and glucagon at 60-180 min, total and late glucagon response were higher in CPL than CPH group, while fasting glucagon and early glucagon response adjusted for glucose were comparable between CPL and CPH group. The higher late glucagon response and late glucagon response adjusted for glucose were associated with lower peak C-peptide in T1D. The higher late glucagon response and lower peak C-peptide were associated with the higher value of Delta glucose at 180 min. Conclusion Stimulated C-peptide levels affect the paradoxical increase in postprandial glucagon secretion in patients with T1D, especially late glucagon response. The exaggerated postprandial glucagon secretion further stimulates the elevation of postprandial glucose in patients with T1D.
引用
收藏
页数:11
相关论文
共 43 条
  • [1] Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?
    Albrechtsen, Nicolai J. Wewer
    Hartmann, Bolette
    Veedfald, Simon
    Windelov, Johanne A.
    Plamboeck, Astrid
    Bojsen-Moller, Kirstine N.
    Idorn, Thomas
    Feldt-Rasmussen, Bo
    Knop, Filip K.
    Vilsboll, Tina
    Madsbad, Sten
    Deacon, Carolyn F.
    Holst, Jens J.
    [J]. DIABETOLOGIA, 2014, 57 (09) : 1919 - 1926
  • [3] ROLE OF HYPERGLUCAGONEMIA IN MAINTENANCE OF INCREASED RATES OF HEPATIC GLUCOSE OUTPUT IN TYPE-II DIABETICS
    BARON, AD
    SCHAEFFER, L
    SHRAGG, P
    KOLTERMAN, OG
    [J]. DIABETES, 1987, 36 (03) : 274 - 283
  • [4] The Impact of Pancreatic Beta Cell Heterogeneity on Type 1 Diabetes Pathogenesis
    Benninger, Richard K. P.
    Dorrell, Craig
    Hodson, David J.
    Rutter, Guy A.
    [J]. CURRENT DIABETES REPORTS, 2018, 18 (11)
  • [5] Too much glucagon, too little insulin - Time course of pancreatic islet dysfunction in new-onset type 1 diabetes
    Brown, Rebecca J.
    Sinah, Ninet
    Rother, Kristina I.
    [J]. DIABETES CARE, 2008, 31 (07) : 1403 - 1404
  • [6] β-Cell-Mediated Signaling Predominates Over Direct α-Cell Signaling in the Regulation of Glucagon Secretion in Humans
    Cooperberg, Benjamin A.
    Cryer, Philip E.
    [J]. DIABETES CARE, 2009, 32 (12) : 2275 - 2280
  • [7] Glucagon therapeutics: Dawn of a new era for diabetes care
    Davidson, Jaime A.
    Holland, William L.
    Roth, Michael G.
    Wang, May-yun
    Lee, Young
    Yu, Xinxin
    McCorkle, Sara K.
    Scherer, Philipp E.
    Unger, Roger H.
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2016, 32 (07) : 660 - 665
  • [9] Insulin Resistance Is Accompanied by Increased Fasting Glucagon and Delayed Glucagon Suppression in Individuals With Normal and Impaired Glucose Regulation
    Faerch, Kristine
    Vistisen, Dorte
    Pacini, Giovanni
    Torekov, Signe S.
    Johansen, Nanna B.
    Witte, Daniel R.
    Jonsson, Anna
    Pedersen, Oluf
    Hansen, Torben
    Lauritzen, Torsten
    Jorgensen, Marit E.
    Ahren, Bo
    Holst, Jens Juul
    [J]. DIABETES, 2016, 65 (11) : 3473 - 3481
  • [10] The influence of glucagon on postprandial hyperglycaemia in children 5 years after onset of type 1 diabetes
    Fredheim, Siri
    Andersen, Marie-Louise M.
    Porksen, Sven
    Nielsen, Lotte B.
    Pipper, Christian
    Hansen, Lars
    Holst, Jens J.
    Thomsen, Jane
    Johannesen, Jesper
    Mortensen, Henrik B.
    Svensson, Jannet
    [J]. DIABETOLOGIA, 2015, 58 (04) : 828 - 834